SLC5A2 and hydrops fetalis: In a prespecified meta-analysis including results from the 12,251 patientsincluded in the EMPEROR-Preserved and DELIVER trials, SGLT2 inhibitors reducedthe primary composite outcome of cardiovascular death or first hospitalizationfor HF, without evidence of significant heterogeneity between trials.